Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors inside the central nervous program, conolidine modulates alternate molecular targets. A Science Advancements review uncovered that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://lilliani542ghh2.aboutyoublog.com/profile